Tricuspid valve repair and replacement for infective endocarditis

Indian J Thorac Cardiovasc Surg. 2024 May;40(Suppl 1):100-109. doi: 10.1007/s12055-023-01650-0. Epub 2023 Dec 16.

Abstract

Infective endocarditis represents a challenging and life-threatening clinical condition affecting native and prosthetic heart valves, endocardium, and implanted cardiac devices. Right-sided infective endocarditis account for approximately 5-10% of all infective endocarditis and are often associated with intravenous drug use, intracardiac devices, central venous catheters, and congenital heart disease. The tricuspid valve is involved in 90% of right-side infective endocarditis. The primary treatment of tricuspid valve infective endocarditis is based on long-term intravenous antibiotics. When surgery is required, different interventions have been proposed, ranging from valvectomy to various types of valve repair to complete replacement of the valve. Percutaneous removal of vegetations using the AngioVac system has also been proposed in these patients. The aim of this narrative review is to provide an overview of the current surgical options and to discuss the results of the different surgical strategies in patients with tricuspid valve infective endocarditis.

Supplementary information: The online version contains supplementary material available at 10.1007/s12055-023-01650-0.

Keywords: Infective endocarditis; Tricuspid valve; Tricuspid valve repair; Tricuspid valve replacement.

Publication types

  • Review